CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- PositionReturn on equity is -103.3%, lower than 95% of its Medical Devices peers (median 2.5%)
- FinancialsAltman Z-Score -2.6: distress zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
482.60MUSDvs all stocks (USD)
Revenue (TTM)
106.99MUSDvs all stocks (USD)
Profit Margin
-17.86%vs Medical Devices peers
Beta
1.95xvs all stocks
52-Week Change
37.30%vs all stocks
Market Capitalization
482.60MUSDvs all stocks (USD)
Enterprise Value
500.83MUSDvs all stocks (USD)
Forward P/E
-64.65xvs Medical Devices peers
Price to Sales (TTM)
4.51xvs Medical Devices peers
Price to Book (MRQ)
40.52xvs Medical Devices peers
Enterprise to Revenue
4.68xvs Medical Devices peers
Enterprise to EBITDA
-42.17xvs Medical Devices peers
Gross Margin
82.83%vs Medical Devices peers
Profit Margin
-17.86%vs Medical Devices peers
Operating Margin
-22.53%vs Medical Devices peers
Return on Assets (TTM)
-7.47%vs Medical Devices peers
Return on Equity (TTM)
-103.27%vs Medical Devices peers
Revenue (TTM)
106.99MUSDvs all stocks (USD)
Revenue per Share (TTM)
3.19USDUpdated Sep 28, 2026Quarterly Revenue Growth
17.10%vs Medical Devices peers
Gross Profit (TTM)
82.79MUSDvs all stocks (USD)
EBITDA (TTM)
-11.88MUSDvs all stocks (USD)
Net Income (TTM)
-16.17MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-2.95%vs Medical Devices peers
Operating Cash Flow (TTM)
-11.24MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-2.63MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Revenue
99.99MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
22.77MUSDFY2025 · Dec 31, 2025Gross Profit
77.22MUSDFY2025 · Dec 31, 2025Operating Income
-16.34MUSDvs all stocks (USD)
Pre-tax Income
-21.46MUSDFY2025 · Dec 31, 2025Net Income
-21.46MUSDFY2025 · Dec 31, 2025EBIT
-14.01MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-12.06MUSDFY2025 · Dec 31, 2025Research & Development
27.89MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
65.67MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
2.82MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
7.46MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-21.46MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-16.16MUSDFY2025 · Dec 31, 2025Free Cash Flow
-16.49MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
21.81MUSDFY2025 · Dec 31, 2025Interest Paid
6.20MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-21.46MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.95MUSDFY2025 · Dec 31, 2025Stock-based Compensation
11.09MUSDFY2025 · Dec 31, 2025Other Non-cash Items
775.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-1.83MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-730.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-5.95MUSDFY2025 · Dec 31, 2025Capital Expenditures
-332.00KUSDFY2025 · Dec 31, 2025Sale of Investments
0.00USDFY2025 · Dec 31, 2025Net Investing Cash Flow
-332.00KUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
58.44MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-60.51MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-49.55MUSDFY2025 · Dec 31, 2025Other Financing Charges
-543.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
17.73MUSDFY2025 · Dec 31, 2025Shares Outstanding
34.28MSharesUpdated Sep 28, 2026Float Shares
25.42MSharesUpdated Sep 28, 2026Shares Short
956.22KSharesUpdated Sep 28, 2026Short Ratio
7.33daysvs all stocks
Short % of Shares Outstanding
3.21%vs all stocks
% Held by Insiders
4.47%vs all stocks
% Held by Institutions
97.33%vs all stocks
Total Cash (MRQ)
51.70MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.51USDUpdated Sep 28, 2026Total Debt (MRQ)
69.93MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
5.88xvs Medical Devices peers
Current Ratio (MRQ)
4.94xvs Medical Devices peers
Book Value per Share (MRQ)
0.3470USDUpdated Sep 28, 2026Total Assets
105.56MUSDvs all stocks (USD)
Total Current Assets
94.07MUSDFY2025 · Dec 31, 2025Total Liabilities
86.53MUSDFY2025 · Dec 31, 2025Total Non-current Assets
11.49MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
68.72MUSDFY2025 · Dec 31, 2025Total Current Liabilities
17.81MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
21.69MUSDFY2025 · Dec 31, 2025Other Short-term Investments
39.37MUSDFY2025 · Dec 31, 2025Accounts Receivable
14.68MUSDFY2025 · Dec 31, 2025Inventory
16.90MUSDFY2025 · Dec 31, 2025Accounts Payable
2.22MUSDFY2025 · Dec 31, 2025Short-term Debt
2.12MUSDFY2025 · Dec 31, 2025Deferred Revenue
141.00KUSDFY2025 · Dec 31, 2025Long-term Debt
68.72MUSDFY2025 · Dec 31, 2025Common Stock (Book)
34.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-552.41MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
19.03MUSDvs all stocks (USD)
52-Week Low
9.22USDUpdated Sep 28, 202652-Week High
19.60USDUpdated Sep 28, 202652-Week Change
37.30%vs all stocks
Beta
1.95xvs all stocks
50-Day MA
14.51USDUpdated Sep 28, 2026200-Day MA
15.40USDUpdated Sep 28, 2026Avg 10-Day Volume
149.78KSharesUpdated Sep 28, 2026Avg 30-Day Volume
138.99KSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-0.4700USDUpdated Sep 28, 2026Other Income / Expense
-486.00KUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is -103.3%, lower than 95% of its Medical Devices peers (median 2.5%)Significant
Return on equity: -1.03Industry median: 0.03Industry P5: -0.59Peers compared: 102
Debt-to-equity is 5.88×, higher than 95% of its Medical Devices peers (median 0.11×)Significant
Debt-to-equity: 5.88Industry median: 0.11Industry P95: 1.28Peers compared: 102
Price-to-book is 40.52×, higher than 95% of its Medical Devices peers (median 2.51×)Significant
Price-to-book: 40.52Industry median: 2.51Industry P95: 12.98Peers compared: 102
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.83Profit Margin: -0.18
Significant cash reserves alongside high leverageNotable
Cash (USD): 51,699,000Total Debt (USD): 69,931,000Debt-to-Equity: 5.88
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 4.94Altman Z-Score: -2.60
Financial Health
Altman Z-Score -2.6: distress zoneCritical
Altman Z-Score: -2.60
Low earnings qualitySignificant
Earnings Quality Score: -0.63
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Assembly Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Huaren Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Tibet Aim Pharm Inc.
Tier 1ProductionApproval-Gated PipelineRule
Chison Medical Technologies Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Cheng Yi Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Capricor Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Daewoong Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Regenxbio Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Wuhan Hiteck Biological Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Arvinas Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk